Zobrazeno 1 - 10
of 385
pro vyhledávání: '"Evandro de, Azambuja"'
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Autor:
Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, Ferdinando Riccardi, Carmela Mocerino, Valentina Guarneri, Eleonora Mioranza, Giancarlo Bisagni, Elisa Gasparini, Fabio Puglisi, Alexandro Membrino, Antonella Ferro, Vincenzo Adamo, Filippo Giovanardi, Stefano Tamberi, Sara Donati, Elisabetta Landucci, Laura Biganzoli, Sara Piccinini, Simona Pastorino, Evandro de Azambuja, Francesca Poggio, Matteo Lambertini, Lucia Del Mastro
Publikováno v:
Breast, Vol 77, Iss , Pp 103769- (2024)
Background: Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET). Patients and methods: The Gruppo Italiano Mammella (GIM) 23-POSTE
Externí odkaz:
https://doaj.org/article/8652f5b50c25499792521c27f09ea97b
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 19-29 (2023)
Externí odkaz:
https://doaj.org/article/4c22bfe0697b4ef6bf3ff0de4f346603
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating
Externí odkaz:
https://doaj.org/article/50f0c9a693404d0bbb0bf5ae3d4ee9c1
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/dc687f42bfdb4ae99f733b9e06b24556
Autor:
Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien, Diogo Martins-Branco, Philippe Aftimos, Evandro de Azambuja, Ahmad Awada
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to th
Externí odkaz:
https://doaj.org/article/7a5ff39dd5c6423c93c2492ba0e8da2b
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/1872bd3c329443328fa10ee0e5e38651
Autor:
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé, Christian Maurer, Sarra El-Abed, Yingbo Wang, Malou Vicente, Saranya Chumsri, Judith Bliss, Judith Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine Piccart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic perfo
Externí odkaz:
https://doaj.org/article/26e9c2c289cb4f0e805a3be45e4ff06d
Autor:
Gilberto Morgan, Evandro de Azambuja, Kevin Punie, Felipe Ades, Kathrin Heinrich, Nicola Personeni, Ramy Rahme, Roberto Ferrara, Kevin Pels, Marina Garassino, Michael von Bergwelt-Baildon, Gilberto Lopes, Fabrice Barlesi, Toni K. Choueiri, Howard Burris, Solange Peters
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 455-463 (2021)
The speed and spread of the COVID-19 pandemic has been affecting the entire world for the past several months. OncoAlert is a social media network made up of more than 140 oncology stakeholders: oncologists (medical, radiation, and surgical), oncolog
Externí odkaz:
https://doaj.org/article/ed3fe74491454e72beab7a65bbe5ad3b
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 8, Iss , Pp 100206- (2022)
Patients with breast cancer undergoing systemic therapies can have mixed response to treatment, with some lesions reducing their dimensions or also, in some cases, disappearing, and others progressing. Of note, breast cancer is an example of tumor he
Externí odkaz:
https://doaj.org/article/6fbda50c18004b509f850f422eb94849